Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$27,000.00
Identification of Therapeutic Targets for NF1-Deficient High Grade Serous Ovarian Carcinomas
EF 2024-25
Résumé
High-grade serous carcinoma is the most common and the most clinically aggressive type of ovarian cancer, as most patients present with widespread disease in the abdominal/pelvic regions. Patients with this disease are typically treated with chemotherapy and surgery as well as a new class of drugs called PARP inhibitors (PARPi) if the cancer tests positive for BRCA1/2 mutation. Patients generally respond well to a combination of these treatments but may acquire treatment resistance. However, more than half of patients with high-grade serous carcinoma have tumors that do not have a BRCA1/2 mutation do poorly because of the lack of effective therapy. About 20% of the patients with this aggressive type of ovarian cancer (including ones lacking BRCA1/2 mutations) carry a mutated gene called neurofibromin (NF1) and drugs that target NF1 mutation or other analogous mutations are available clinically in the treatment of other cancer types. With this in mind, we propose to study whether this tumor characteristic can be explored for therapeutic insights to find new drugs that can help to improve the survival and life of patients with this aggressive ovarian cancer type. Our study includes two primary objectives: firstly, we will study established and engineered experimental models of NF1-inactivated human high-grade serous carcinoma to identify cellular signaling pathways that preferentially activated (therefore targetable) in NF1-inactivated tumors. This will inform and direct the second objective, which is to evaluate drugs that will selectively target these pathways in the experimental models.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
529815
Name
Nechala Isabelle N
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of Therapeutic Targets for NF1-Deficient High Grade Serous Ovarian Carcinomas
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Of The Reproductive System; High-Grade Serous Carcinoma; Nf1 Inactivation; Ovarian Cancer; Therapeutic Targets
Abstract
High-grade serous carcinoma is the most common and the most clinically aggressive type of ovarian cancer, as most patients present with widespread disease in the abdominal/pelvic regions. Patients with this disease are typically treated with chemotherapy and surgery as well as a new class of drugs called PARP inhibitors (PARPi) if the cancer tests positive for BRCA1/2 mutation. Patients generally respond well to a combination of these treatments but may acquire treatment resistance. However, more than half of patients with high-grade serous carcinoma have tumors that do not have a BRCA1/2 mutation do poorly because of the lack of effective therapy. About 20% of the patients with this aggressive type of ovarian cancer (including ones lacking BRCA1/2 mutations) carry a mutated gene called neurofibromin (NF1) and drugs that target NF1 mutation or other analogous mutations are available clinically in the treatment of other cancer types. With this in mind, we propose to study whether this tumor characteristic can be explored for therapeutic insights to find new drugs that can help to improve the survival and life of patients with this aggressive ovarian cancer type. Our study includes two primary objectives: firstly, we will study established and engineered experimental models of NF1-inactivated human high-grade serous carcinoma to identify cellular signaling pathways that preferentially activated (therefore targetable) in NF1-inactivated tumors. This will inform and direct the second objective, which is to evaluate drugs that will selectively target these pathways in the experimental models.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nechala, Isabelle N
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~